BACKGROUND: A proliferation of animal models has not only improved our understanding of inflammatory bowel disease, it has also formed the basis of new treatment strategies. METHODS: A search was conducted using the National Library of Medicine for articles discussing immune therapies for inflammatory bowel disease. This was supplemented by findings from the authors' own laboratory. RESULTS: An overview of the different animal models is presented. These models are used to highlight the recent human trials of immune therapies. Potential future therapies are also discussed. CONCLUSION: Immune therapies have altered the management of patients with inflammatory bowel disease. In future they will influence not only the indications for surgery bu...
In this review, we speculate about future therapeutic approaches for inflammatory bowel diseases (IB...
Despite all of the advances in our understanding of the pathophysiology of inflammatory bowel diseas...
IDI&CA_COLITIS/2019 - Pharmacological modulation of inflammation associated with inflammatory bowel ...
Background/Aims: Inflammatory bowel diseases (IBD) are chronic relapsing diseases of unknown origin...
Inflammatory bowel disease (IBD) represents a chronic, relapsing, remitting, and inflammatory condit...
Inflammatory bowel diseas is consisted of ulcerative colitis (UC) and Crohn's disease (CD). Their pa...
Treatment of Colitis by Epicutaneous Immunotherapy in a Murine Model. Advances in inflammatory bowel...
In the last decade a number of models of chronic intestinal inflammation have been described that re...
Inflammatory Bowel Diseases (IBD) are life-threatening chronic and relapsing disorders of the immune...
Infl ammatory bowel disease (IBD), the most important being Crohn’s disease and ulcerative colitis, ...
Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is a lifelong d...
Crohn disease (CD) and ulcerative colitis (UC) are the two most common forms of chronic inflammatory...
Chronic inflammatory diseases have become one the major challenges of both modern medicine and healt...
BACKGROUND: There is no standardized validated experimental model used to predict human drug respons...
Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract ...
In this review, we speculate about future therapeutic approaches for inflammatory bowel diseases (IB...
Despite all of the advances in our understanding of the pathophysiology of inflammatory bowel diseas...
IDI&CA_COLITIS/2019 - Pharmacological modulation of inflammation associated with inflammatory bowel ...
Background/Aims: Inflammatory bowel diseases (IBD) are chronic relapsing diseases of unknown origin...
Inflammatory bowel disease (IBD) represents a chronic, relapsing, remitting, and inflammatory condit...
Inflammatory bowel diseas is consisted of ulcerative colitis (UC) and Crohn's disease (CD). Their pa...
Treatment of Colitis by Epicutaneous Immunotherapy in a Murine Model. Advances in inflammatory bowel...
In the last decade a number of models of chronic intestinal inflammation have been described that re...
Inflammatory Bowel Diseases (IBD) are life-threatening chronic and relapsing disorders of the immune...
Infl ammatory bowel disease (IBD), the most important being Crohn’s disease and ulcerative colitis, ...
Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is a lifelong d...
Crohn disease (CD) and ulcerative colitis (UC) are the two most common forms of chronic inflammatory...
Chronic inflammatory diseases have become one the major challenges of both modern medicine and healt...
BACKGROUND: There is no standardized validated experimental model used to predict human drug respons...
Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract ...
In this review, we speculate about future therapeutic approaches for inflammatory bowel diseases (IB...
Despite all of the advances in our understanding of the pathophysiology of inflammatory bowel diseas...
IDI&CA_COLITIS/2019 - Pharmacological modulation of inflammation associated with inflammatory bowel ...